This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The approval process for cell and gene therapy candidates is tricky, however, given their high-cost and oft-debated benefit-risk ratio. RFK Jr did not question their importance, and acknowledged panellists’ calls for faster regulatory processes. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. We may still continue to send you service-related and other non-promotional communications. In 2024, Otsuka announced the acquisition of US-based Jnana Therapeutics in a deal worth up to $1.1bn. Sign up for our daily news round-up!
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. We may still continue to send you service-related and other non-promotional communications. This update also suggests we may not see REMS requirements for CD19 and BCMA autologous CAR-T cell therapies in the future,” the research note added.
Better insights into how SDoH affects health can highlight the systemic influences that leave certain groups with worse health outcomes than others, despite similar health insurancecoverage or access. For example, it’s important to consider whether someone has insurance (public or private), a job, and what their income may be.
When Plaid effectively forced financial institutions to take an open-protocol approach to digital interoperability, “Every bank (took) their five-year strategy on digitizing and brought it down into one or two years,” CEO Zach Perret said in an interview with Fortune magazine. The patient’s journey is typically long and complicated ?
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. We may still continue to send you service-related and other non-promotional communications. Editorial content is independently produced and follows the highest standards of journalistic integrity. Sign up for our daily news round-up!
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. We may still continue to send you service-related and other non-promotional communications. Editorial content is independently produced and follows the highest standards of journalistic integrity. Sign up for our daily news round-up!
Porton Advanced will apply its knowledge in viral vector technology and CAR-T cell therapy process development to enhance EVA Pharma’s mission to provide safe, effective, and scalable cancer treatments. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Sign up for our daily news round-up!
These platforms are designed for safe drug production while allowing scaleable manufacturing processes. mRNA vaccine coverage on Pharmaceutical Technology (or Clinical Trials Arena) is supported by Trilink. The trial data indicated dose-dependent protein production at the site without systemic bioavailability. “By
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. We may still continue to send you service-related and other non-promotional communications. Editorial content is independently produced and follows the highest standards of journalistic integrity. Sign up for our daily news round-up!
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. We may still continue to send you service-related and other non-promotional communications. Editorial content is independently produced and follows the highest standards of journalistic integrity. Sign up for our daily news round-up!
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. We may still continue to send you service-related and other non-promotional communications. Elsewhere in the partnership arena, AstraZeneca outlaid $5.2bn to enlist the services of China-based CSPC Pharmaceuticals. Sign up for our daily news round-up!
mRNA vaccine coverage on Pharmaceutical Technology (or Clinical Trials Arena) is supported by Trilink. GSK also has an FDA-approved vaccine in the form of Arexvy, though its label only covers those at risk in individuals aged between 50 through 59 years , along with the standard indication of ages 60 and over.
Disrupting ACIP’s work introduces dangerous uncertainty about which vaccines will continue to be covered and whether families will have to pay out of pocket for routine immunisations,” the non-profit said. Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content